Bioverativ to Present at Citi’s 12th Biotech Conference

WALTHAM, Mass.--(BUSINESS WIRE)-- Bioverativ Inc. (NASDAQ: BIVV) announced today that it will present at Citi’s12th Biotech Conference. The event will be webcast live on Wednesday, September 6, 2017 at 12:00 p.m. EDT. To access the live webcast, please visit Bioverativ’s Investors page at investors.bioverativ.com. An archived version of the webcast will be available following the presentation.

About Bioverativ

Bioverativ (NASDAQ: BIVV) is a global biotechnology company dedicated to transforming the lives of people with hemophilia and other rare blood disorders through world-class research, development and commercialization of innovative therapies. Launched in 2017 following separation from Biogen Inc., Bioverativ builds upon a strong heritage of scientific innovation and is committed to actively working with the blood disorders community. The company’s mission is to create progress for patients where they need it most and its hemophilia therapies when launched represented the first major advancements in hemophilia treatment in more than two decades. For more information, visit www.bioverativ.com or follow @bioverativ on Twitter.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170830006133/en/

INVESTOR CONTACT:
Bioverativ
Susan Altschuller, Ph.D., +1 781-663-4360
[email protected]

Source: Bioverativ

You May Also Be Interested In

• Lucky Hand Mining Game LLC, Subsidiary of Buscar Company (OTC: CGLD), Launches Telegram Mini App and Unveils Long-Term Strategy for Gold Rush-Inspired Gaming Ecosystem
• Hyperscale Data Receives Utility "Will Serve" Determination for Approximately 125 Additional Megawatts at One of its Montana Sites
• OpenVC™ Announces Close of OPEN Unicorn Fund, Expanding Access to Private Market Leaders